Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

Fig. 3

Subgroup analysis of progression-free survival (a) and overall survival (b). HR hazard ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group, BCLC Barcelona Clinic Liver Cancer, TACE transarterial chemoembolization, cTACE conventional transarterial chemoembolization, DEB-TACE drug-eluting beads transarterial chemoembolization, HCC hepatocellular carcinoma

Back to article page